Search clinical trials for: Ustekinumab Injection [Stelara]

Total 9820 results

Wolfson Medical Center
Sheba Medical Center

Not yet recruiting

Stelara and Diet Trial for Crohn"s Disease

Crohn Disease

Israel
BioFactura Australia Pty Ltd.
Avance Clinical Pty Ltd.

Completed

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

Psoriasis

Australia, New Zealand
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
Jewish General Hospital

Completed

Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis

Type 1 Diabetes Mellitus

Canada
Bioeq GmbH

Completed

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

Plaque Psoriasis

Poland, Estonia, Ukraine, Georgia
National Institute of Allergy and Infectious Diseases...

Completed

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

CVID Enteropathy | Gastrointestinal Inflammation Associated With CVID

United States
Millennium Magnetic Technologies, LLC

Unknown

Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO (PCD=OOALZ)

Alzheimer Disease

United States
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
University Medical Center Groningen
Janssen-Cilag B.V.

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (HiTS)

Hidradenitis Suppurativa

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis (U-POPS)

Psoriasis | Arthritis, Juvenile | Juvenile Psoriatic Arthritis

United States
Tufts Medical Center
Centocor, Inc.

Completed

Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis (PPP)

Moderate to Severe Palmar Plantar Psoriasis

United States
Janssen Research & Development, LLC

Terminated

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
NYU Langone Health

Terminated

Induction Optimization With Stelara for Crohn's Disease

Crohn Disease

United States
University of British Columbia
Juvenile Diabetes Research Foundation

Unknown

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)

Type 1 Diabetes

Canada
Charite University, Berlin, Germany

Completed

Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis (TOPAS)

Ankylosing Spondylitis

Germany
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

Psoriasis

China
Celltrion

Completed

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

Healthy Subjects

New Zealand
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, France, United States, Hungary, Japan, United Kingdom, Germany, Poland, Argentina
Janssen-Cilag International NV

Recruiting

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (STELARA)

Psoriasis

Belgium, United Kingdom, Austria, Denmark, France, Germany, Netherlands, Norway, Russian Federation, Switzerland, Greece
Janssen Korea, Ltd., Korea

Completed

Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab) (STELARA CD PMS)

Crohn Disease

Korea, Republic of
Alvotech Swiss AG

Completed

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Psoriasis

Georgia, Estonia, Poland, Ukraine
Alvotech Swiss AG
Iqvia Pty Ltd

Completed

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

Psoriasis

Australia, New Zealand
Biocon Biologics UK Ltd

Active, not recruiting

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis (STELLAR-2)

Moderate to Severe Chronic Plaque Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

Healthy

United States
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Groupe d'Etude Therapeutique des Affections Inflammatoires...
Janssen, LP

Recruiting

USTekinumab in Fistulising Perianal Crohn's Disease (USTAP) (USTAP)

Crohn's Disease

France
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations

Healthy

United States
University of California, San Diego
Janssen Biotech, Inc.; The Organization of Teratology Information Specialists

Recruiting

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

Psoriasis | Pregnancy | Crohn Disease | Psoriatic Arthritis

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease

China
Celltrion

Completed

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

Psoriasis

Estonia
Chang Gung Memorial Hospital

Unknown

The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)

Psoriasis With Cell-derived Microparticles

Taiwan
Second Affiliated Hospital, School of Medicine,...
Sixth Affiliated Hospital, Sun Yat-sen University; Second Affiliated Hospital... and other collaborators

Recruiting

Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Crohn Disease | Intestinal Stricture | Stricture; Bowel

China
Dong-A ST Co., Ltd.
Meiji Seika Pharma Co., Ltd.

Completed

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis (Opportuniti)

Moderate to Severe Chronic Plaque Psoriasis

United States
Alimentiv Inc.
Takeda

Not yet recruiting

VOICE-Early Response to Vedolizumab and Ustekinumab in Participants With Crohn's Disease: A Prospective Observational Study (VOICE)

Crohn's Disease
Amgen

Completed

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Poland, Canada, Germany, Estonia, Georgia, Hungary, Latvia
Rockefeller University

Completed

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

Atopic Dermatitis

United States
Janssen Research & Development, LLC

Completed

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease (TRIDENT)

Crohn Disease

United States, France, Poland, Ukraine, Germany, Belgium, Bulgaria, Romania, Japan, Canada, Korea, Republic of, Russian Federation, Hungary, United Kingdom
Bio-Thera Solutions

Completed

Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Crohn Disease

United States, Korea, Republic of, Netherlands, France, Austria, Italy, United Kingdom, Germany, Russian Federation, Spain, Czechia, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Arthritis, Juvenile

United States, France, United Kingdom, Turkey, Spain, Argentina, Germany, Italy, Poland, Denmark
Amgen

Completed

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Poland, Estonia, Germany, Hungary, Latvia, Lithuania
University of British Columbia
Juvenile Diabetes Research Foundation; Janssen, LP

Recruiting

Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) (UST1D2)

Type 1 Diabetes Mellitus

Canada
RANI Therapeutics

Completed

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

Healthy Volunteers

Australia
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Takayasu Arteritis

Japan
National Medical Research Center for Children's...

Recruiting

Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

Congenital Ichthyosis

Russian Federation
Universitaire Ziekenhuizen KU Leuven
Janssen, LP

Recruiting

Stelara fOr ChRonic AntibioTic rEfractory pouchitiS (SOCRATES)

Pouchitis

Belgium
Janssen Scientific Affairs, LLC

Completed

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

Crohn Disease

United States, Belgium, Korea, Republic of, Netherlands, Italy, United Kingdom, Canada, France, Australia, Bulgaria, Poland, Germany, Serbia, Czechia, Russian Federation, Spain, Brazil, Hungary
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (EMBRACE 1)

Psoriasis

Belgium, Germany, Italy, Poland, Spain, France, Greece, Hungary
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (UNIFI Jr)

Colitis, Ulcerative

Belgium, United States, United Kingdom, Israel, Japan, Germany, Hungary, Russian Federation, Poland
Janssen Research & Development, LLC

Completed

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Poland, Germany, Spain, Mexico, Australia, Taiwan, Argentina, Hungary

Search clinical trials for: Ustekinumab Injection [Stelara]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations